We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
New UK Centre for Cell Manufacturing is Validating TAP’s CellBase CT System
News

New UK Centre for Cell Manufacturing is Validating TAP’s CellBase CT System

New UK Centre for Cell Manufacturing is Validating TAP’s CellBase CT System
News

New UK Centre for Cell Manufacturing is Validating TAP’s CellBase CT System

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "New UK Centre for Cell Manufacturing is Validating TAP’s CellBase CT System"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The CellBase CT, which is the second system in TAP’s automated cell culture range to be sited at Loughborough University, was funded by the East Midlands Development Agency (emda). The system will be used by researchers in the EPSRC Centre for Innovative Manufacturing in Regenerative Medicine initially to validate their GMP process of culturing autologous stem cells for clinical use. When the validation process is complete in 2011, the centre aims to collaborate with European and US biotech and pharma companies to produce early stage clinical material for use in trials to treat a number of disease areas which could benefit from a cell therapy approach.

The CellBase CT at the EPSRC Centre for Innovative Manufacturing in Regenerative Medicine has been rigorously designed for aseptic, unattended operation. The system has the capacity to process up to 90 T-flasks at one time and expand cells from multiple patients in parallel, ensuring the centre’s scientists can continuously culture sufficient quantities of clinical grade stem cells in a contamination-free, GMP compliant environment.

David J. Williams, Professor of Healthcare Engineering at Loughborough University explained: “Collaborating with TAP again is a natural continuation of the successful five year REMEDI consortium, in which both TAP and Loughborough were involved.  Our team at Loughborough is built of intensely practical engineers and biologists who recognise and can deliver what regulators mean by GMP compliance in our new facility. TAP is one of the few companies willing to take the time to ensure our CellBase CT delivers the stringent quality levels required and this is why we continue working with TAP.”

Tim Ward, Director of Cell Culture at TAP commented: “We are delighted that we have been able to work with Loughborough to refine our automated cell culture system and help them to validate it for this important application.  We believe that the new CellBase CT system is a major step forward in providing scalable and cost-effective production of autologous cell therapies, and that it will ultimately enable more patients to benefit from this exciting new area of medicine.  We will be previewing our new system at Invitrogen’s Cell Therapy Summit next week (3-5 Nov, Carlsbad) and look forward to meeting development scientists and discussing how CellBase CT could support their programmes to produce a validated method of affordable cell therapy production.”

Advertisement